Perspective Therapeutics, Inc.
CATX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $1,434 | $7,104 | $10,795 |
| % Growth | -100% | -79.8% | -34.2% | – |
| Cost of Goods Sold | $0 | $0 | $5,470 | $6,179 |
| Gross Profit | $0 | $1,434 | $1,634 | $4,616 |
| % Margin | – | 100% | 23% | 42.8% |
| R&D Expenses | $41,638 | $21,311 | $2,602 | $2,582 |
| G&A Expenses | $26,613 | $20,967 | $10,866 | $6,621 |
| SG&A Expenses | $26,613 | $21,064 | $14,214 | $9,425 |
| Sales & Mktg Exp. | $0 | $97 | $3,228 | $2,804 |
| Other Operating Expenses | $24,089 | $0 | $0 | $0 |
| Operating Expenses | $92,340 | $42,375 | $17,426 | $12,007 |
| Operating Income | $10,459 | -$40,941 | -$15,182 | -$7,391 |
| % Margin | – | -2,855% | -213.7% | -68.5% |
| Other Income/Exp. Net | -$91,835 | $835 | $512 | $119 |
| Pre-Tax Income | -$81,376 | -$40,106 | -$14,670 | -$7,272 |
| Tax Expense | -$2,097 | -$2,651 | $0 | -$119 |
| Net Income | -$79,279 | -$46,508 | -$14,670 | -$7,153 |
| % Margin | – | -3,243.2% | -206.5% | -66.3% |
| EPS | -1.23 | -0.85 | -0.27 | -0.13 |
| % Growth | -44.7% | -214.8% | -107.7% | – |
| EPS Diluted | -1.23 | -0.85 | -0.27 | -0.13 |
| Weighted Avg Shares Out | 64,425 | 54,906 | 54,906 | 54,906 |
| Weighted Avg Shares Out Dil | 64,425 | 54,906 | 54,906 | 54,906 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,515 | $934 | $1,122 | $119 |
| Interest Expense | -$48 | $84 | $0 | $119 |
| Depreciation & Amortization | $0 | $981 | $344 | $248 |
| EBITDA | $10,459 | -$39,960 | -$14,838 | -$7,391 |
| % Margin | – | -2,786.6% | -208.9% | -68.5% |